Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Ensemble Therapeutics Corporation ' Product Pipeline Review ' 2012

154 views

Published on

Ensemble Therapeutics Corporation ' Product Pipeline Review ' 2012 Summary Global Market Direct's pharmaceuticals report, "Ensemble Therapeutics Corporation - Product Pipeline Review - 2012" provides data on the Ensemble Therapeutics Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Ensemble Therapeutics Corporation's corporate website, SEC filings, investor presentations and featured press releases, both from Ensemble Therapeutics Corporation and industry-specific third party sources, put together by Global Markets Direct's team. Scope - Ensemble Therapeutics Corporation - Brief Ensemble Therapeutics Corporation overview including business description, key information and facts, and its locations and subsidiaries.- Review of current pipeline of Ensemble Therapeutics Corporation human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.- Product profiles for late stage and clinical stage products of Ensemble Therapeutics Corporation with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Ensemble Therapeutics Corporation's pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Ensemble Therapeutics Corporation's strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Ensemble Therapeutics Corporation in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Ensemble Therapeutics Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Ensemble Therapeutics Corporation. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Ensemble Therapeutics Corporation and identify potential opportunities in those areas.

  • Be the first to comment

  • Be the first to like this

Ensemble Therapeutics Corporation ' Product Pipeline Review ' 2012

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Ensemble Therapeutics Corporation Product Pipeline Review 2012Published on December 2012 Report SummaryEnsemble Therapeutics Corporation Product Pipeline Review 2012SummaryGlobal Market Directs pharmaceuticals report, "Ensemble Therapeutics Corporation - Product Pipeline Review - 2012" provides dataon the Ensemble Therapeutics Corporations research and development focus. The report includes information on currentdevelopmental pipeline, complete with latest updates, and features on discontinued and dormant projects.This report is built using data and information sourced from Global Markets Directs proprietary databases, Ensemble TherapeuticsCorporations corporate website, SEC filings, investor presentations and featured press releases, both from Ensemble TherapeuticsCorporation and industry-specific third party sources, put together by Global Markets Directs team.Scope- Ensemble Therapeutics Corporation - Brief Ensemble Therapeutics Corporation overview including business description, keyinformation and facts, and its locations and subsidiaries.- Review of current pipeline of Ensemble Therapeutics Corporation human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,across the globe.- Product profiles for late stage and clinical stage products of Ensemble Therapeutics Corporation with complete description of theproducts developmental history, mechanism of action, therapeutic class, target and major milestones.- Recent updates of the Ensemble Therapeutics Corporations pipeline in the last quarter.- Key discontinued and dormant projects.- Latest news and deals relating to the products.Reasons to buy- Evaluate Ensemble Therapeutics Corporations strategic position with total access to detailed information on its product pipeline.- Assess the growth potential of Ensemble Therapeutics Corporation in its therapy areas of focus.- Identify new drug targets and therapeutic classes in the Ensemble Therapeutics Corporations R&D portfolio and develop keystrategic initiatives to reinforce pipeline in those areas.- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.- Exploit collaboration and partnership opportunities with Ensemble Therapeutics Corporation.- Avoid Intellectual Property Rights related issues.- Explore the dormant and discontinued projects of Ensemble Therapeutics Corporation and identify potential opportunities in thoseareas.Ensemble Therapeutics Corporation Product Pipeline Review 2012 (From Slideshare) Page 1/6
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Table of ContentTable of ContentsTable of Contents 2List of Tables 4List of Figures 4Ensemble Therapeutics Corporation Snapshot 5Ensemble Therapeutics Corporation Overview 5Key Information 5Key Facts 5Ensemble Therapeutics Corporation Research and Development Overview 6Key Therapeutic Areas 6Ensemble Therapeutics Corporation Pipeline Review 8Pipeline Products by Stage of Development 8Pipeline Products Monotherapy 9Ensemble Therapeutics Corporation Pipeline Products Glance 10Ensemble Therapeutics Corporation Early Stage Pipeline Products 10Pre-Clinical Products/Combination Treatment Modalities 10Discovery Products/Combination Treatment Modalities 11Ensemble Therapeutics Corporation Drug Profiles 12Drug 1 For Inflammation 12Product Description 12Mechanism of Action 12R&D Progress 12Drug 2 For Inflammation 13Product Description 13Mechanism of Action 13R&D Progress 13Drug For Diabetes 14Product Description 14Mechanism of Action 14R&D Progress 14Drug For Oncology 15Product Description 15Mechanism of Action 15R&D Progress 15Drug For Pain 16Product Description 16Mechanism of Action 16R&D Progress 16Interleukin-17 Antagonist 17Product Description 17Mechanism of Action 17R&D Progress 17Ensemble Therapeutics Corporation Pipeline Analysis 18Ensemble Therapeutics Corporation Pipeline Products by Therapeutic Class 18Ensemble Therapeutics Corporation Product Pipeline Review 2012 (From Slideshare) Page 2/6
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Ensemble Therapeutics Corporation Pipeline Products by Route of Administration 19Ensemble Therapeutics Corporation Pipeline Products By Mechanism of Action 20Ensemble Therapeutics Corporation Recent Pipeline Updates 21Ensemble Therapeutics Corporation Locations And Subsidiaries 22Head Office 22Other Locations & Subsidiaries 22Ensemble Therapeutics Corporation, Recent Developments 23Ensemble Therapeutics Corporation- Press Release 23Nov 12, 2012: Ensemble Therapeutics Presents Oral Efficacy Of Small Molecule Targeting IL-17 For Inflammation In PreclinicalStudies 23Oct 29, 2012: Ensemble Therapeutics To Present Poster On Interleukin-17 At 2012 ACR Annual Meeting 24Financial Deals Landscape 25Ensemble Therapeutics Corporation, Deals Summary 25Ensemble Therapeutics Corporation, Pharmaceuticals & Healthcare, Deal Details 26Partnerships 26Ensemble Therapeutics Enters Into Drug Discovery Agreement With Boehringer Ingelheim 26Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 28Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb 29Appendix 31Methodology 31Coverage 31Secondary Research 31Primary Research 31Expert Panel Validation 31Contact Us 32Disclaimer 32List of TablesEnsemble Therapeutics Corporation, Key Information 5Ensemble Therapeutics Corporation, Key Facts 5Ensemble Therapeutics Corporation Pipeline by Indication, 2012 7Ensemble Therapeutics Corporation Pipeline by Stage of Development, 2012 8Ensemble Therapeutics Corporation Monotherapy Products in Pipeline, 2012 9Ensemble Therapeutics Corporation Pre-Clinical, 2012 10Ensemble Therapeutics Corporation Discovery, 2012 11Ensemble Therapeutics Corporation Pipeline By Therapeutic Class, 2012 18Ensemble Therapeutics Corporation Pipeline By Route of Administration, 2012 19Ensemble Therapeutics Corporation Pipeline Products By Mechanism of Action, 2012 20Ensemble Therapeutics Corporation Recent Pipeline Updates, 2012 21Ensemble Therapeutics Corporation, Other Locations 22Ensemble Therapeutics Corporation, Deals Summary 25Ensemble Therapeutics Enters Into Drug Discovery Agreement With Boehringer Ingelheim 26Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 28Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb 29Ensemble Therapeutics Corporation Product Pipeline Review 2012 (From Slideshare) Page 3/6
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!List of FiguresEnsemble Therapeutics Corporation Pipeline by Indication, 2012 7Ensemble Therapeutics Corporation Pipeline by Stage of Development, 2012 8Ensemble Therapeutics Corporation Monotherapy Products in Pipeline, 2012 9Ensemble Therapeutics Corporation - Pipeline Products By Mechanism of Action, 2012 20Ensemble Therapeutics Corporation Product Pipeline Review 2012 (From Slideshare) Page 4/6
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Ensemble Therapeutics Corporation Product Pipeline Review 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 1 500.00 Quantity: _____ Site License--USD 3 000.00 Quantity: _____ Corporate License--USD 4 500.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Ensemble Therapeutics Corporation Product Pipeline Review 2012 (From Slideshare) Page 5/6
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Ensemble Therapeutics Corporation Product Pipeline Review 2012 (From Slideshare) Page 6/6

×